Novo Nordisk (NVO) announced that the US Food and Drug Administration has approved three new indications for once-weekly Sogroya injection 5 mg, 10 mg, or 15 mg, a long-acting growth hormone. Sogroya is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, short stature born Small for Gestational Age and with no catch-up growth by 2 years of age, or growth failure associated with Noonan Syndrome. Sogroya is also indicated for children aged 2.5 years and older and adults with growth hormone deficiency.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Advances New First‑in‑Human Obesity Drug NNC6989‑0001 Into Testing
- Novo Nordisk’s CagriSema Trial Update: What Investors Should Watch in the GLP‑1 Race
- Novo Nordisk, Vivtex announce partnership to develop oral obesity/diabetes drugs
- AI Daily: AMD, Meta expand partnership
- Mixed options sentiment in Novo Nordisk with shares down 2.46%